Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Ovarian Cancer
What hormonal therapy, if any, would you offer for adjuvant treatment of stage IC ER-/PR+ low grade serous ovarian cancer?
Related Questions
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
Does the PFS and OS data presented at ESMO 2025 for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
For a borderline ovarian tumor that has been resected with BSO and hysterectomy, would you consider endocrine therapy if found to be ER-positive?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
What are your top takeaways from SGO 2025?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
How does your management and counseling of a patient with ovarian cancer change when they have significant persistent disease after neoadjuvant chemotherapy?
